Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nuntius Therapeutics
AddedMar 22, 2024
UpdatedJul 1, 2026
Nuntius Therapeutics

Nuntius Therapeutics

Seed

Developing genetic therapies for rare diseases. Delivering large payloads to correct cells.

HQ
London, Greater London, GB
Founded
2021
Accelerator
Y Combinator logoY CombinatorW21
Overview
Compare
Fundraising
Employees
Website

Nuntius Therapeutics is a biotechnology company focused on advancing RNA and DNA therapies. Their core mission is to overcome the challenge of delivering large genetic payloads into specific cells, a critical hurdle in the development of DNA, RNA, and CRISPR therapies. The company's primary focus is on developing treatments for rare diseases that currently lack effective cures.

Nuntius Therapeutics has established a pipeline of potential therapies targeting rare genetic disorders. By addressing the fundamental issue of payload delivery, the company aims to unlock the full potential of genetic therapies and make significant strides in treating previously incurable conditions. Their innovative approach positions them at the forefront of genetic medicine development.

Nuntius Therapeutics - Similar Companies

Nextrna Therapeutics logo

Nextrna Therapeutics

Code Biotherapeutics logo

Code Biotherapeutics

codebiotx.com

Apertura Gene Therapy logo

Apertura Gene Therapy

aperturagtx.com

Intergalactic Therapeutics logo

Intergalactic Therapeutics

Nvelop Therapeutics logo

Nvelop Therapeutics

Sixfold Bioscience logo

Sixfold Bioscience

sixfold.bio

Nephrogen logo

Nephrogen

Locanabio logo

Locanabio

Lattice Therapeutics logo

Lattice Therapeutics

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

Interius BioTherapeutics logo

Interius BioTherapeutics

interiusbio.com

Nanotransfer logo

Nanotransfer

nanotransfer.bio

GuideRx logo

GuideRx

Strm.Bio logo

Strm.Bio

strm.bio

Excepgen logo

Excepgen

excepgen.com

Nuntius Therapeutics - Quick Facts

Who are Nuntius Therapeutics' competitors?

Companies similar to Nuntius Therapeutics include Nextrna Therapeutics, Code Biotherapeutics, Apertura Gene Therapy and Intergalactic Therapeutics.

When was Nuntius Therapeutics founded?

Nuntius Therapeutics was founded in 2021.

Where is Nuntius Therapeutics' headquarters located?

Nuntius Therapeutics' headquarters is located in London, Greater London, GB.

When was Nuntius Therapeutics' last funding round?

Nuntius Therapeutics' most recent funding round was for $125k (USD) in March 2021.

How much has Nuntius Therapeutics raised to-date?

As of Mar 22, 2021, Nuntius Therapeutics has raised a total of $125k (USD).

How many employees does Nuntius Therapeutics have?

Nuntius Therapeutics has 13 employees as of Feb 24, 2024.

Nuntius Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Genetic Therapies
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software